2013 ASCO Annual Meeting Press Program Announced

For immediate release
April 29, 2013

Contact
Kelly Baldwin
571-483-1365
kelly.baldwin@asco.org

ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) today announced the studies to be featured in the 2013 ASCO Annual Meeting press program. The press program will highlight major new advances in cancer research, including:

- The latest findings in precision medicine, where new drug therapies are taking aim at molecular targets on cancer and immune cells
- New prevention findings for cervical and breast cancers
- Large, Phase III trials exploring new treatments to prevent cancer recurrences
- New strategies aimed at improving the quality and value of cancer care and maximizing patients' quality of life.

The ASCO Annual Meeting will take place in Chicago, between Friday, May 31 and Tuesday, June 4, and attract more than 30,000 oncology professionals from around the world. This year more than 5,000 abstracts will be presented or published at the Meeting.

The majority of Annual Meeting abstracts will be publicly posted on www.asco.org on Wednesday, May 15 at 6:00 PM EDT. ASCO will host an embargoed presscast for media at 12:00 noon EDT that day to highlight several important studies. Plenary, Late-breaking and Clinical Review abstracts will be released on site at the meeting. The full media and embargo policies, press conference schedule at-a-glance and media FAQ are available on ASCO’s Annual Meeting Media Resource Center, including detailed information about updates to the embargo policies and timeline for Plenary, Late-Breaking and Clinical Review abstracts.

EMBARGOED PRESSCAST

Wednesday, May 15, 12:00 noon EDT (Studies embargoed until May 15 at 6:00 PM EDT)

Research to be highlighted includes:

- An observational study assessing the effect of cardiorespiratory fitness on cancer incidence
• A long-term study exploring whether surveillance-alone is sufficient for men in remission of stage I seminoma (Abstract #4502)
• Results of a Phase III study comparing standard-dose and high-dose radiation therapy in patients with advanced non-small cell lung cancer undergoing chemotherapy (Abstract #7501)
• Results from a study examining the use of CT scans to detect relapses in patients with aggressive lymphoma (Abstract #8504)
• An early study evaluating idelalisib (GS-1101), a first-in-class PI3K? inhibitor, for patients with relapsed or treatment-resistant chronic lymphocytic leukemia (Abstract # 7003)
• Findings from a Phase I trial exploring the effect of the anti-PD-L1 antibody drug MPDL3280A in patients with locally advanced or metastatic solid tumors (Abstract #3000)
• A Phase I study evaluating the combined effect of two immunotherapies – the anti-PD-1 antibody drug nivolumab and ipilimumab (Yervoy) – in patients with advanced melanoma (Abstract #9012^)

RESEARCH TO BE RELEASED ON-SITE AT THE ANNUAL MEETING

ASCO will hold daily press conferences to highlight important research being presented in that day’s conference sessions. ASCO may hold additional press conferences on additional topics throughout the meeting. Press conferences will highlight the following research:

Saturday, June 1, 8:00-9:00 AM CDT (Studies embargoed until June 1 at 6:30 AM CDT):

• Results from a Phase III trial evaluating the targeted drug pazopanib (Votrient) as a maintenance therapy for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer (Abstract #LBA5503)
• Data from a Phase II study exploring the addition of GM-CSF to ipilimumab (Yervoy) in patients with metastatic melanoma (Abstract #CRA9007)
• Long-term follow-up data on the safety and efficacy of single-agent nivolumab (an anti-PD-1 antibody) in patients with advanced melanoma (Abstract #CRA9006^)
• Findings from a Phase II study comparing the targeted drug selumetinib to standard temozolomide (Temodar) chemotherapy in patients with Gq/11 mutated melanoma of the eye (Abstract #CRA9003)
• Data on the prevalence of oral HPV infection among the spouses of patients with HPV-positive oropharyngeal cancer (Abstract #CRA6031)
• Results from a Phase III study comparing first-line treatment with cetuximab (Erbitux) or bevacizumab (Avastin), together with FOLFIRI chemotherapy, in patients with metastatic colorectal cancer (Abstract #LBA3506)

Sunday, June 2, 8:00-9:00 AM CDT (All studies presented in this press conference will be featured in ASCO’s plenary session; studies embargoed until June 2 at 6:30 AM CDT):

• Results of a Phase III trial exploring the effect of bevacizumab (Avastin) in patients with newly diagnosed glioblastoma (Abstract #1)
• Findings from a large, randomized cervical cancer screening trial conducted in India that assessed the impact of bi-annual cervical cancer screening with simple vinegar (acetic acid), performed by public health workers (Abstract #2)
• Findings from a Phase III study evaluating the addition of bevacizumab (Avastin) to standard chemotherapy for recurrent and metastatic cervical cancer (Abstract #3)
• Results from the first Phase III trial evaluating the targeted drug sorafenib (Nexavar) in patients....
with advanced, radioactive iodine-refractory differentiated thyroid cancer, the most common
form of advanced thyroid cancer (Abstract #4)
- Study exploring the effects of continuing tamoxifen therapy for 10 years, versus standard 5-
  year therapy, among women who have successfully completed breast cancer therapy (Abstract
  #5)

**Monday, June 3, 8:00-9:00 AM CDT** (Studies embargoed until June 3 at 6:30 AM CDT):

- A Phase III study comparing two widely used dosing schedules – weekly and dose-dense – of
  adjuvant paclitaxel (Taxol) chemotherapy for breast cancer (Abstract #CRA1008)
- Findings from a trial examining the prevalence of inherited high-risk genetic mutations
  associated with breast cancer among African American women with breast cancer (Abstract
  #CRA1501)
- A study evaluating the impact of oncology drug shortages on patient care (Abstract #CRA6510)
- A randomized Phase II study examining the Hsp90 inhibitor ganetespib in combination with
docetaxel (Taxotere) versus docetaxel alone as second-line therapy for patients with advanced
lung cancer (Abstract #CRA8007)
- A Phase III trial comparing radiotherapy with standard surgery of the axillary lymph nodes, in
women with early-stage, sentinel lymph node-positive breast cancer (Abstract #LBA1001)

**MEDIA RESOURCES**

- **Media Registration**: To register for the embargoed May 15 Presscast or to attend the ASCO
  Annual Meeting, please visit ASCO’s Media Headquarters at [http://mediahq.asco.org](http://mediahq.asco.org). **Please
  note**: Registration must be completed no later than Tuesday, May 14 to participate in the
  embargoed May 15 Presscast. Annual Meeting pre-registration for U.S. and international
journalists is required and must be completed by Wednesday, May 22.
- **Online Resources**: A full suite of resources for media are available at the Annual Meeting
  Media Resource Center
- **On-site Resources**: A full-service Press Room will provide wireless Internet, telephones, fax,
  scanner, printers, and limited computer workstations with Internet access. A limited number of
private interview rooms will also be available. Leading cancer experts will be available to speak
with members of the press upon request.
- **Photos** from the ASCO Annual Meeting sessions and press briefings will be available through
ASCO’s [online Photo Gallery](http://mediahq.asco.org) each day of the Meeting. Media requests for specific photos are
welcome and accommodated to the greatest degree possible.
- **ASCO’s Virtual Meeting** will provide online access to all major sessions following the meeting.
- Access to the **Virtual Press Room** – an online repository of corporate and institutional press
materials created by third-party organizations.
- ASCO’s Cancer Progress .Net offers a detailed, interactive timeline of advances against 17 of
the most common cancers, including several highlighted in the Annual Meeting press program.
- Cancer.Net, ASCO’s award-winning cancer information website, provides comprehensive,
doctor-approved information on more than 120 cancer types.

**About ASCO:**

Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world’s leading
professional organization representing physicians who care for people with cancer. With more than
35,000 members, ASCO is committed to improving cancer care through scientific meetings,
educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds groundbreaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit asco.org. Patient-oriented cancer information is available at Cancer.Net.